-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-9592 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AZD-9592 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AZD-9592 in Solid Tumor Drug Details: AZD-9592 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TSHA-102 in Rett Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TSHA-102 in Rett Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TSHA-102 in Rett Syndrome Drug Details: TSHA-102 (TGTX-104) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASP-8374 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASP-8374 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASP-8374 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: ASP-8374...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EXS-617 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EXS-617 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EXS-617 in Pancreatic Cancer Drug Details: EXS-617 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zolbetuximab in Metastatic Adenocarcinoma of The Pancreas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zolbetuximab in Metastatic Adenocarcinoma of The Pancreas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zolbetuximab in Metastatic Adenocarcinoma of The Pancreas Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMG-305 in Uterine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMG-305 in Uterine Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMG-305 in Uterine Cancer Drug Details: Monoclonal antibody is under development...
-
Sector Analysis
NewFuture of Pharma – Looking Ahead to 2024
This report provides a summary of the near and long-term future of the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot and prioritize them within your sectors.
-
Product Insights
NewNet Present Value Model: Astellas Pharma Inc’s AT-845
Empower your strategies with our Net Present Value Model: Astellas Pharma Inc's AT-845 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Astellas Pharma Inc’s Fezolinetant
Empower your strategies with our Net Present Value Model: Astellas Pharma Inc's Fezolinetant report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.